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Abstract
Several studies were done investigating thyroid function in patients 
with epilepsy. However the results of different studies were con-
flicting or controversial. This study aimed to evaluate thyroid hor-
monal changes and their relationship to thyroid volume in epileptic 
adults on long-term treatment with antiepileptic drugs (AEDs). This 
study included 135 adults with idiopathic epilepsy with mean age 
of 32.32±4.34years, duration of illness of 10.52±5.08 years and on 
treatment with carbamazepine (CBZ), valproate (VPA) or CBZ+VPA for 
a mean duration of 8.66±3.32years. The serum levels of free thy-
roxine (fT4), triiodothyronine (fT3), and thyroid-stimulating hormone 
(TSH) were assessed. Thyroid volume was measured using ultrasonog-
raphy. Compared to control subjects, patients had significant lower 
fT4 (p<0.01) and fT3 (p<0.01) and higher levels of TSH (p<0.0001). 
The majority of patients with reduced fT4 also had reduced fT3 and 
increased TSH levels. Nearly 26% of the patients had enlargement 
of the thyroid gland (p<0.001). Patients on polytherapy had more 
thyroid volume compared to patients on monotherapy (p<0.05) and 
patients on VPA had more thyroid volume compared to patients on 
CBZ (p<0.03). All patients were clinically euthyroid. Significant cor-
relations were identified between fT4 concentrations and duration of 
illness, dose, serum level and duration of AEDs treatment, fT3 and 
TSH concentrations and between thyroid volume and fT4, fT3 and 
TSH concentrations. In conclusion, CBZ and VPA as mono- or poly- 
therapies may cause thyroid hormonal and structural abnormalities. 
Thyroid enlargement is due to associated subclinical hypothyroidsm. 
This data have implications suggesting prevention strategies.  
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Introduction
Epilepsy is a common chronic medical problem and 
often requires long-term therapy, which may even 
continue throughout life (1). Disturbances in endo-
crine hormones have been reported in patients with 
epilepsy and with some antiepileptic drugs (AEDs), 
among are thyroid hormones. The majority of the 
studies suggested that the changes of thyroid hor-
mones in epileptics were due to the effect of some 
AEDs and not the due to the disease itself (2,3). 
Earlier studies frequently reported abnormal thyroid 
hormonal levels with enzyme inducing AEDs [carba-
mazepine (CBZ), phenytoin (PHT) and phenobarbital 
(PB)]. These abnormalities included reduced serum 
concentrations of total thyroxine (T4), free T4 (fT4), 
tri-iodothyronine (T3), free T3 (fT3), free T4-index 
(fT4I), free T3-index (fT3I), thyroxine binding globu-
lin (TBG) and increased concentrations of thyroid 
stimulating hormone (TSH) (2-6). Also earlier stud-
ies reported normal thyroid hormonal levels with 
non-enzyme inducing AED (valproate or VPA) which 
included normal concentrations of T4 (7-9), T3, T3 
uptake (T3U) and thyrotropin (TSH) and thyrotro-
pin releasing hormone (TRH) stimulation (4,7,10-16). 
Further studies reported that non-enzyme inducing 
AED (valproate or VPA) is also associated with thy-
roid hormonal dysfunction (17-25). None of these 
studies reported overt manifestations of thyroid ab-
normalities. Reduction in fT4 and increase in TSH 
levels were reported as early as one to three months 
after starting treatment with CBZ, PB or VPA (20, 
25). Also, previous studies demonstrated that the 
changes induced by these drugs are transient (4,16). 
Studies reported increase in serum concentrations 
of fT4, fT3 and reduction of TSH and restoration of 
euthyroid state several months following AED with-
drawal even after years of treatment (26,27) or with 
L-thyroxine substitutive supplement (28). 
Few studies were done to assess thyroid volume 
in patients with epilepsy and on AEDs. Some stud-
ies reported ultrsongraphic evidence of thyroid 
enlargement (goiter). Also, these studies reported 
significant correlation between thyroid volume and 
thyroid hormonal abnormalities (5,29). 
Induction of metabolism of thyroid hormones by the 
hepatic microsomal enzyme system has been sug-
gested as the main mechanism for decreased serum 
T4, fT4, T3 and fT3 concentrations with enzyme 
inducing AEDs. The reduction in thyroid hormone 
concentrations in the periphery is associated with 
compensatory increase in the serum TSH enhance-
ment. Some suggested that interference with hy-
pothalamic regulation of thyroid function by AEDs 
seems a possible mechanism for thyroid hormonal 
abnormalities with AEDs (30). The development of 
high   levels of TSH more than 5mIU/mL is known 
as subclinical hypothyroidism (SCH). However, the 
mechanism of thyroid hormonal with non-enzyme 
inducing VPA is unclear. The increase in the concen-
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tration of T3 reported by some authors with AEDs 
(13) could be explained as a mechanism of the body 
to counteract the impact of diminishing production 
of T4 through a preferential thyroidal secretion of T3 
and enhanced conversion of T4 into T3 particularly 
in the early stage of development of hypothyroid-
ism. Some suggested that increased T3 may result 
from augmented T4 to T3 conversion rate due to 
accelerated T4 metabolic clearance (31).
Aim of work
Although thyroid function has been frequently inves-
tigated in patients with epilepsy, however conflict-
ing data exist for the influence and mechanisms of 
AEDs on thyroid function. In addition, data regard-
ing the predictors for thyroid enlargement (goiter) 
with epilepsy are still unknown. This study aimed 
to investigate the functional and volume changes 
of the thyroid gland in adults with epilepsy and on 
long-term AEDs. 
Materials and Methods
Subjects
This is a cross-sectional study. It included 135 adult 
patients with idiopathic epilepsy (male = 88, fe-
males = 47) with age ranged between 20 to 50 
years (mean: 32.32 ± 4.34), duration of illness of 
5 to 20 years (mean: 10.52 ± 5.08) and on chron-
ic treatment with CBZ (n = 65), VPA (n = 30) or 
CBZ+VPA (n = 40) for a duration ranged between 6 
to 15 years (mean: 8.66 ± 3.32). Table (1) showed 
the demographic, clinical and laboratory features 
of the studied patients. Epilepsy type was classified 
according to the recommendations of the Interna-
tional League Against Epilepsy (32). Patients were 
recruited from the out-patient epilepsy clinic of As-
siut and Al-Azhar University Hospitals, Assiut, Egypt. 
Sixty normal healthy subjects matched for age, sex 
and socioeconomic status were chosen as control 
subjects for statistical comparisons. Control subjects 
were recruited from the general population. The 
protocol of the study was reviewed and approved 
by the ethical committee of Assiut and Al-Azhar 
University Hospitals and all subjects in this study 
gave their informed consent before participation.
All participants were subjected to full medical, en-
docrinological and neurological histories and exami-
nations. Biological variables collected included: age, 
gender and body mass index (BMI). Seizures were 
analyzed determining seizure type, duration of ill-
ness, duration of treatment with AEDs and the de-
gree of response to AEDs. Patients were considered 
controlled on AEDs when seizure free for ≥ 1 year. 
Patients with diseases other than epilepsy, iodine 
deficiency conditions, family history of thyroid dis-
ease, history of thyroid surgery, manifestations of a 
pituitary mass or of hypopituitarism (which suggest 
the presence of central hypothyroidism) or taking 
regular medication(s) beside AEDs, were excluded.
Specimen collection and analysis
After an overnight fast and patients were seizure 
free for at least 72 hours [as any postictal central 
hormonal dysfunction is recognized to reverse with-
in hours], blood samples were drawn at (8.00-10.00 
a.m.) for routine testing as complete blood count 
(CBC), fasting blood glucose (FBG), and serum lev-
els of creatinine, aspartat amino transferase (AST), 
alanine amino transferase (ALT) and gamma glu-
tamyl transferase (GGT). The rest of serum sample 
was kept frozen at -70ºC in aliquots for the assay 
of serum levels of AEDs, fT3, fT4 and TSH.  Hor-
monal concentrations and serum drug levels were 
measured as part of the investigation in batched as-
says. For all patient and control subjects, the serum 
concentrations of fT4, fT3 and TSH were measured 
by immunoenzymetric assay kits (IMMULITE repro-
ductive hormone assays by kits obtained from DPC 
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or Diagnostic Products Corporation, Los Angeles, 
USA as described by the manufacturer (33-35). The 
serum level of AED(s) were determined in the thera-
peutic drug monitoring (TDM) lab, Assiut University 
Hospital, Assiut Egypt, by fluorescence polarization 
immunoassay system of Abbott (EPIA) using TDxFLX 
apparatus (Abbott Lab, Wiesbaden, Germany) (17).
 
Ultrasonography (US)  
of the thyroid
Ultrasonography was done by the same radiolo-
gist using a real time ultrasound equipment ca-
pable of B-mode imaging, pulsed wave duplex 
scanning, color Doppler flow imaging and power 
Doppler imaging (GE, LOGIQ 3 Color Doppler 
Machine, Korea). A 7.5-MHz linear transducer B-
mode was used for measurement. The volume 
of each lobe was calculated using the formula 
for a prolate ellipse: (Volume = 0.5 [length (L) 
x anterior-posterior depth (D) x transverse width 
(W)]. Longitudinal and transverse images of the 
right and left thyroid lobes were obtained to 
show their maximal linear dimensions. All mea-
surements were performed with electronic cali-
pers on the frozen B-scan image (36).
Statistical analysis
Data were expressed as means ± SD. Calculations 
were done with the statistical package SPSS for 
windows, version 12.0 (SPSS Inc., Chicago, IL, USA). 
Student’s t-test was used to compare between 
means. Pearson’s correlation coefficient was used 
to look for association between different metabolic 
variables. For all tests, values of P<0.05 (two-tailed) 
were considered statistically significant.
Results
Patients had normal ALT and AST and GGT. Com-
pared to control subjects, patients had significant 
lower serum levels of fT4 (p<0.01) and fT3 (p<0.01) 
and higher levels of TSH (p<0.0001). Marked abnor-
malities were observed in patients on polytherapy 
(CBZ+VPA) compared to patients on monotherapy 
Table 1. Demographic and clinical features of the 
studied patients
Age; years 20 - 50 (32.32 ± 4.34)
Gender (Male/Female) 88/47
Body mass index 
(BMI); kg/m2
16 - 40 (25.89 ± 2.69)
Duration of illness; 
years
5 - 20 (10.52 ± 5.08)
Type of epilepsy:
Generalized tonic-clonic 
epilepsy
58 (42.96%)
Complex partial/Partial 
epilepsy with secondary 
generalization
77 (57.04%)
Antiepileptic drugs (AEDs) utilized:
Carbamazepine (CBZ) 65 (48.15%)
Valproate (VPA) 30 (22.22%)
CBZ+VPA 40 (29.63%)
Dose of AED; mg/day
CBZ 400 - 1200 (650.55 ± 289.83)
VPA 1000 – 2250 (1250.00 ± 250.00)
Duration of 
treatment; years
6 - 15 (8.66 ± 3.32)
Serum drug level; µg/ml
CBZ 4.5 - 11.0 (8.02 ± 3.05)
VPA 70.04 - 105.50 (90.55 ± 25.50)
Degree of control on AED(s)
Controlled (seizure free 
for ≥ 1 year)
85 (62.96%)
Uncontrolled 50 (37.04%)
Values are expressed as mean ± SD and number (%).
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(CBZ or VPA). The majority of patients with reduced 
serum levels of fT4 had also reduced levels of fT3 and 
increased levels of TSH. Nearly 26% of the patients 
had increase in the thyroid gland volume (p<0.001) 
(versus 6.7% for control subjects). Patients on poly-
therapy had more thyroid gland volume compared 
to patients on monotherapy (p<0.05) and patients 
on VPA had more thyroid gland volume compared 
to patients on CBZ (p<0.03) (table 2). All patients 
were clinically euthyroid. Compared to patients 
without SCH (n = 59), patients with SCH (n = 76) 
were older, had longer duration of illness, higher 
doses of AEDs, higher serum levels of AEDs and 
longer duration of treatment on AEDs (table 3). No 
significant differences were identified in the serum 
levels of fT4, fT3, TSH or thyroid volume between 
patients who were controlled or those who were 
uncontrolled on AEDs. Correlations between demo-
Table 2. Thyroid hormonal and volume results of the studied groups
Variable Patients 
(n = 135)
Patients on CBZ
(n = 65)
Patients on 
VPA
(n = 30)
Patients on 
CBZ+VPA
(n = 40)
Controls
(n = 60)
fT4; ng/ml 76 (56.30%)
1.06-4.63
1.98±±0.38
31 (47.69%)
1.26-3.37
1.44±±0.50
18 (60%)
1.06-4.63
1.84±±0.30
26 (65%)
0.26-2.86
0.96±±0.30
5 (8.33%)
1.75-3.85
2.39±±0.45
P1
P2
P3
0.010
-
-
0.010
>0.05
0.045
0.010
-
0.036
0.001
-
-
-
-
-
fT3; pg/ml 52 (38.52%)
1.52-4.64
1.90±±0.22
23 (35.38%)
2.23-4.43
2.56±±0.32
11 (36.67%)
1.67-4.64
2.05±±0.66
18 (45%)
1.52-3.86
1.85±±0.72
2 (3.33%)
1.73-4.95
3.86±±0.53
P1
P2
P3
0.010
-
-
0.010
>0.05
>0.05
0.010
-
>0.05
0.010
-
-
-
-
-
TSH; mIU/L 56 (41.48%)
3.37-12.00
7.68±±0.42
24 (36.92%)
3.37-10.52
6.42±±0.34
10 (33.33%)
2.76-11.43
6.88±±0.64
22 (55%)
4.22-12.00
8.06±±0.38
7 (11.67%)
2.85-4.60
2.54±±0.67
P1
P2
P3
0.0001
-
-
0.0001
>0.05
0.010
0.0001
-
0.010
0.0001
-
-
-
-
-
Thyroid volume; ml 35* (25.93%)
10.54-58.40
24.64±±3.30
8* (12.31%)
10.54-47.84
22.55±±3.62
9* (30%)
12.54-48.45
25.08±±2.32
18* (45%)
14.08-58.40
28.96±±2.08
4* (6.67%)
9.75-42.82
14.53±±2.64
P1
P2
P3
0.001
-
-
0.001
0.030
0.010
0.001
-
0.043
0.001
-
-
-
-
-
Data are expressed as means ± SD, number (%) of patients with abnormal results. 
fT3, free triiodothyronine; fT4, free thyroxine; TSH, thyroid stimulating hormone
P1: significance versus controls, P2: significance versus VPA, P3: significance versus CBZ+VPA
*: Number of patients with thyroid enlargement (goiter)
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Table 3. Demographic and clinical features and thyroid volume in relationship to the presence or 
absence of subclinical hypothyroidism 
Demographic and clinical features Patients with 
subclinical 
hypothyroidism
(n = 76)
Patients without 
subclinical 
hypothyroidism
(n = 59)
P-value
Age 38.53 ± 2.66 30.02 ± 3.82 0.010
Gender (Male/Female) 45/31 43/16 -
Body mass index (BMI) 22.54 ± 2.40 26.64 ± 3.66 0.089
Duration of illness 15.63 ± 3.53 8.86 ± 2.45 0.001
Type of epilepsy:
Generalized tonic-clonic epilepsy 22 (28.95%) 36 (61.02%) -
Complex partial/Partial epilepsy with 
secondary generalization
54 (71.05%)
23 (38.98%) -
Antiepileptic drugs (AEDs) utilized
CBZ 32 (42.11%) 33 (55.93%) -
VPA 18 (23.68%) 12 (20.34%) -
CBZ+VPA 26 (34.21%) 14 (23.73%) -
Dose of AED 
CBZ 850.00 ± 200.50 400.50 ± 150.00 0.001
VPA 1400.00 ± 250.00 1000.00 ± 350.80 0.010
Duration of treatment 13.45 ± 4.46 6.47 ± 2.82 0.001
Serum drug level
CBZ 10.45 ± 1.62 6.88 ± 1.45 0.010
VPA 100.40 ± 25.35 70.65 ± 15.25 0.001
Degree of control on AED(s)
Controlled (seizure free for ≥ 1 year) 54 (71.05%) 31 (52.54%) -
Uncontrolled 22 (28.95%) 28 (47.46%) -
Thyroid volume 35* (46.05%) 59 (0%) -
24.64±±3.30 15.64 ±± 3.53 0.001
Values are expressed as mean ± SD and number (%)
*: Number of patients with thyroid gland enlargement (goiter)
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graphic, clinical, laboratory and US characteristics of 
the studied group revealed significant correlations 
between the followings: 1) fT4 concentrations and 
duration of illness (r = -0.362, p = 0.043), dose of 
AED (CBZ: r = -0.508, p = 0.001; VPA: r = -0.638, 
p = 0.001), serum level of AED (CBZ: r = -0.742, 
p = 0.001; VPA: r = -0.570, p = 0.001), duration 
of treatment (r = -0.456, p = 0.01), fT3 concentra-
tions (r = 0.456, p = 0.01), TSH concentrations (r = 
-0.854, p = 0.0001) and thyroid volume (r = -0.576, 
p = 0.001), 2) fT3 concentrations and fT4 concentra-
tions (r = 0.456, p = 0.01), TSH concentrations (r = 
-0.632, p = 0.001) and thyroid volume (r = -0.388, 
p = 0.042), 3) TSH concentrations and dose of AED 
(CBZ: r = 0.623, p = 0.001; VPA: r = 0.568, p = 
0.007), duration of treatment (r = 0.577, p = 0.006), 
fT4 concentrations (r = -0.854, p = 0.0001), fT3 
concentrations (r = -0.632, p = 0.001) and thyroid 
volume (r = 0.680, p = 0.001), and 4) No significant 
correlations were found between serum levels of 
fT4, fT3 or TSH  and GGT concentrations. 
Discussion
The results of this study indicate that adults with 
epilepsy and on long-term treatment with enzyme-
inducing and non-enzyme inducing old AEDs ex-
perience the followings: 1) high frequency of sub-
clinical hypothyroidism (SCH) as evidenced by lower 
serum concentrations of fT4 and fT3 and higher 
concentrations of TSH. These changes occurred re-
gardless to the type of epilepsy or the degree of 
control on AEDs, 2) a significant frequency of pa-
tients with SCH had ultrasonographic evidence of 
thyroid enlargement (goiter), 3) patients on poly-
therapy showed marked abnormalities and more 
increase in thyroid volume compared to those on 
monotherapy, 4) age, duration of illness, duration of 
treatment and dose and serum level of AEDs are risk 
factors for SCH. The latter is a risk factor for thyroid 
enlargement, and 5) The presence of abnormalities 
of thyroid hormones and volume with CBZ and VPA 
and normal GGT (a marker of liver enzyme induc-
tion), highly suggest the presence of mechanisms 
other that enzyme induction that may contribute 
to thyroid hormonal and structural abnormalities 
among patients with epilepsy. 
In this study, SCH was reported in approximately 
half of the epileptic patients (i.e. reduced fT4 and 
fT3 and increased TSH in 56.30%, 38.52% and 
41.48% versus 8.33%, 3.33% and 11.67% of con-
trol subjects, respectively). With CBZ, we reported 
SCH in 1/3-1/2 of patients (i.e. reduced fT4 and 
fT3 and increased TSH in 47.69%, 35.38% and 
36.92%). With CBZ, Yılmaz et al. (25) reported SCH 
in 13.9%, Isojarvi et al. (8) reported reduced levels 
of T4 in 53.3%, fT4 in 28.9% and Eiris-Punal et 
al. (15) reported increased levels of TSH in 8.2% 
(versus 3.6% for controls). With VPA, we reported 
SCH in 1/3-2/3 of patients (i.e. reduced fT4 and 
fT3 and increased TSH in 47.69%, 35.38% and 
36.92%). Previous studies reported SCH in 25.2% 
(19), 19.6% (22), 52.4 (23), 26% (24) and 28% (25) 
with VPA. We reported SCH in more than 1/3-1/2 
of patients on combined therapy (CBZ + VPA) (fT4 
= 65%; fT3 = 45%; TSH = 55%). Isojarvi et al. (8) 
reported reduced levels of fT4 in 50-100% of pa-
tients on CBZ-VPA. Previous studies reported that 
polytherapy was associated with SCH (19,23). The 
altered thyroid function during CBZ medication and 
been attributed to induction of the hepatic P-450 
enzyme system and the consequent increase in the 
metabolism of thyroid hormones (3-6,11,37). The 
presence of normal GGT and the presence of thy-
roid abnormalities with VPA highly suggest that 
there are other mechanisms which induce thyroid 
hormonal abnormalities in patients with epilepsy 
and on AEDs. Hypothalamic interference of regula-
tion of thyroid hormone production by AEDs seems 
possible. In addition, some authors suggested that 
there are other mechanisms which may result in 
thyroid abnormalities with CBZ other than enzyme 
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induction. Villa et al. (38) suggested that inhibition 
of iodine uptake by the thyroid gland might be one 
of the mechanisms by which CBZ can induce thy-
roid dysfunction. Surks and DeFesi (39) showed that 
patients taking CBZ medication had low fT4 and 
fT3 levels when serum samples were analyzed by 
a commercial procedure from diluted serum, but 
not when an ultrafiltration method from undiluted 
serum was used. The authors concluded that their 
results further support the view that hepatic P-450 
enzyme induction is not the main or the only rea-
son for decreased thyroid hormone concentrations 
during CBZ treatment. However, the mechanism of 
thyroid dysfunction with VPA is still unknown. 
In this study, thyroid enlargement was reported in 
one fourth of patients (26% versus 6.67% controls) 
which represents 46.05% of patients with lab evi-
dence of SCH. The higher frequency of patients with 
thyroid enlargement were on combined therapy 
(CBZ + VPA) (45%) followed by those on VPA (30%). 
Previous studies reported thyroid enlargement with 
enzyme-inducing and non-enzyme inducing AEDs 
(5,29,40). Hegedüs et al. (5) reported increased thy-
roid volume with CBZ (range: 13-66 ml, mean: 25 
ml; versus range: 9-44 ml, mean: 16 ml for controls; 
p<0.010). The authors reported an associated be-
tween the thyroid volume and reduced serum levels 
of T4, fT4I and fT3I and increased serum level of thy-
roglobulin but normal serum levels of T3, T3RU and 
TSH. Chakova et al. (29) reported thyroid enlarge-
ment in 18.2% of the children on long-term treat-
ment with AEDs. Clinical signs of initial hyperplasia 
of the thyroid gland were observed in 13.64%. The 
ultrasound examination revealed slight structural 
changes, decreased colloid uptake, and strip-like 
sprouts in 63.6% particularly with combined AEDs 
(polytherapy) (54.55%). The authors reported as-
sociated between thyroid enlargement and abnor-
malities in the thyroid hormones and thyrotropin 
serum concentration (22.73%). However in contrast, 
normal thyroid volume was reported despite lower 
levels of T4, fT4 and T3. with CBZ and VPA (41). The 
identified significant correlations between thyroid 
volume and thyroid hormones abnormalities found 
in this and other studies highly suggest that the 
increase in thyroid volume is probably a compensa-
tory mechanism due to the low serum concentra-
tions of fT4 and compensatory reduced concentra-
tions of fT3 and enhanced concentrations of TSH 
regardless of the type of AEDs (enzyme-inducing 
versus non-enzyme inducing AEDs).
Despite the strength of this study, it has some limita-
tions: 1) the recruitment of the study group from a 
tertiary care center (a University hospital) with more 
severe cases and this explains the high percentage of 
thyroid hormonal and volume abnormalities. How-
ever, it should be kept in mind that SCH is a relatively 
common condition with incidence between 3 to 7% 
in the general population (42). The prevalence of the 
disease is approximately 20% (43). Hence probably, 
such frequency rates for developing SCH might be 
increased among the patients with epilepsy group of 
population, which is also common, and 2) because of 
the cross-sectional nature of the present study, it was 
not possible to know temporal relationship between 
thyroid dysfunction to the use of AEDs. However, 
such limitations could only be overcomed through a 
longitudinal and multi-center study design. 
Conclusions
CBZ and VPA as mono- or poly- therapies may 
cause thyroid hormonal and structural abnormali-
ties. The increased thyroid volume is probably due 
to associated subclinical hypothyroidism (SCH). This 
data indicates the importance of monitoring thyroid 
function in patients with epilepsy and on treatment 
with AEDs. This data also may have implications 
suggesting prevention strategies.  
NEUROLOGY AND NEUROSCIENCE
ISSN: 2386-687X
2015
Vol. 1 No. 2
doi: 10.3823/349
© Under License of Creative Commons Attribution 3.0 License 9
Conflict of interests
The authors declare that they have no competing 
interests. Authors did not receive fund for this work 
and all were authors’ responsibility.  
References
 1. Hauser WA, Annegers JF, Kurland LT. Incidence of Epilepsy and 
Unprovoked Seizures in Rochester, Minnesota: 1935-1984. 
Epilepsia 1993;34(3),453-468.
 2. Magiera J. Functional disorders of the hypothalamo-pituitary-
thyroid axis in epilepsy. Neurol Neurochir Pol 1987;21(6):498-
503. 
 3. Yuksel A, Yalcin E, Cenani A. Influence of long-term 
carbamazepine treatment on thyroid function. Acta Paediatr 
Jpn 1993;35(3):229-232.
 4. Strandjord RE, Aanderud S, Myking OL, Johannessen SI. Influence 
of carbamazepine on serum thyroxine and triiodothyronine in 
patients with epilepsy. Acta Neurol Scand 1981;63(2):111-121.
 5. Hegedüs L, Hansen JM, Lühdorf K, Perrild H, Feldt-Rasmussen 
U, Kampmann JP. Increased frequency of goitre in epileptic 
patients on long-term phenytoin or carbamazepine treatment. 
Clin Endocrinol (Oxf) 1985;23(4):423-429.
 6. Connacher AA, Borsey DQ, Browning MC, Davidson DL, Jung 
RT. The effective evaluation of thyroid status in patients on 
phenytoin, carbamazepine or sodium valproate attending an 
epilepsy clinic. Postgrad Med J 1987;63(744):841-845.
 7. Larkin JG, Macphee GJ, Beastall GH, Brodie MJ. Thyroid 
hormone concentrations in epileptic patients. Eur J Clin 
Pharmacol 1989;36(3):213-216.
 8. Isojarvi JI, Pakarinen AJ, Myllyla VV. Thyroid function with 
antiepileptic drugs. Epilepsia 1992;33(1):142-148.
 9. Caksen H, Dulger H, Cesur Y, Odabas D, Tuncer O, Atas B.No 
effect of long-term valproate therapy on thyroid and parathyroid 
functions in children. Int J Neurosci 2002;112(11):1371-1374.
10. Liewendahl K, Majuri H, Helenius, T. Thyroid function test in 
patients on long-term treatment with various anticonvulsant 
drugs. Clin Endocrinol 1978;8(3):185-191.
11. Rootwelt K, Ganes T, Johannessen SI.Effect of carbamazepine, 
phenytoin and phenobarbitone on serum levels of thyroid 
hormones and thyrotropin in humans. Scand J Clin Lab Invest 
1978;38(8):731-736.
12. Bentsen KD, Gram L, Veje A. Serum thyroid hormones and 
blood folic acid during monotherapy with carbamazepine or 
valproate. Acta Neurol Scand 1983;67(4);235-241.
13. Ericsson UB, Bjerre I, Forsgren M, Ivarsson SA.Thyroglobulin 
and thyroid hormones in patients on long-term treatment 
with phenytoin, carbamazepine, and valproic acid. Epilepsia 
1985;26(6):594-596.
14. Isojarvi JIT, Pakarinen AJ, Ylipalosaari, PJ, Myllyla VV. Serum 
hormones in male patients with epilepsy patients receiving 
anticonvulsant medication. Arch Neurol 1990;47(6):670-676.
15. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, Lojo-
Rocamonde S, Novo-Rodriguez I, Castro-Gago M. Long-
term treatment of children with epilepsy with valproate or 
carbamazepine may cause subclinical hypothyroidism. Epilepsia 
1999;40(12):1761-1766.
16. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F.Thyroid 
hormones in epileptic children receiving carbamazepine and 
valproic acid. Pediatr Neurol 2001;25(1):43-46.
17. Hamed SA, Hamed EA, Kandil MR, El-Shereef HK, Abdellah MM, 
Omar H. Serum Thyroid Hormone Balance and Lipid Profile in 
Patients with Epilepsy. Epilepsy Res 2005;66(1-3):173-183.
18. Cansu A, Serdaroglu A, Camurdan O, Hirfanoglu T, Bideci 
A, Gücüyener K.The evaluation of thyroid functions, thyroid 
antibodies, and thyroid volumes in children with epilepsy during 
short-term administration of oxcarbazepine and valproate. 
Epilepsia 2006;47(11):1855-1859.
19. Mikati MA, Tarabay H, Khalil A, Rahi AC, El Banna D, Najjar 
S. Risk factors for development of subclinical hypothyroidism 
during valproic acid therapy. J Pediatr 2007;151(2):178-181. 
 20. Attilakos A, Katsarou E, Prassouli A, Mastroyianni S, Voudris K, 
Fotinou A, Garoufi A. Thyroid function in children with epilepsy 
treated with sodium valproate monotherapy: a prospective 
study. Clin Neuropharmacol 2009;32(1):32-34. 
21. Aggarwal A, Rastogi N, Mittal H, Chillar N, Patil R. Thyroid 
hormone levels in children receiving carbamazepine or valproate. 
Pediatr Neurol 2011;45(3):159-162. 
22. Aygün F, Ekici B, Aydinli N, Aydin BK, Bas F, Tatli B. Thyroid 
hormones in children on antiepileptic therapy. Int J Neurosci 
2012;122(2):69-73. 
23. Kim SH, Chung HR, Kim SH, Kim H, Lim BC, Chae JH, Kim 
KJ, Hwang YS, Hwang H. Subclinical hypothyroidism during 
valproic acid therapy in children and adolescents with epilepsy. 
Neuropediatrics 2012;43(3):135-139.
24. Sahu JK, Gulati S, Kabra M, Arya R, Sharma R, Gupta N, Kaleekal 
T, Reeta Kh, Gupta YK. Evaluation of subclinical hypothyroidism 
in ambulatory children with controlled epilepsy on valproate 
monotherapy. J Child Neurol 2012;27(5):594-597. 
25. Yılmaz U, Yılmaz TS, Akıncı G, Korkmaz HA, Tekgül H.The effect 
of antiepileptic drugs on thyroid function in children. Seizure 
2014;23(1):29-35. 
26. Vainionpää LK, Mikkonen K, Rättyä J, Knip M, Pakarinen AJ, 
Myllylä VV, Isojärvi JI. Thyroid function in girls with epilepsy with 
carbamazepine, oxcarbazepine, or valproate monotherapy and 
after withdrawal of medication. Epilepsia 2004;45(3):197-203.
 27. Lossius MI, Taubøll E, Mowinckel P, Gjerstad L. Reversible 
effects of antiepileptic drugs on thyroid hormones in men and 
2015
Vol. 1 No. 2
doi: 10.3823/349
This article is available from: www. jneuros.com10
NEUROLOGY AND NEUROSCIENCE
ISSN: 2386-687X
women with epilepsy: a prospective randomized double-blind 
withdrawal study. Epilepsy Behav 2009;16(1):64-68. 
28. De Luca F, Arrigo T, Pandullo E, Siracusano MF, Benvenga S, 
Trimarchi F.Changes in thyroid function tests induced by 2 
month carbamazepine treatment in L-thyroxine-substituted 
hypothyroid children. Eur J Pediatr 1986;145(1-2):77-79.
29. Chakova L, Karakhanian E, Dimitrov H, Lutakova E. Effect of 
antiepileptic drugs on the thyroid gland in children with epilepsy 
(preliminary report). Folia Med (Plovdiv)  1998;40(1):80-83.
30. Isojarvi JI, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV. 
Thyroid function in men taking carbamazepine, oxcarbazepine, 
or valproate for epilepsy. Epilepsia 2001,42(7):930-934.
31. Tsukui T, Aizawa T, Yamada T, Kawabe T. Studies on the 
mechanism of goitrogenic action of diphenylthiohydantoin. 
Endocrinology 1978;102(6):1662-1669.
32. Proposal for revised classification of epilepsies and epileptic 
syndromes. Commission on Classification and Terminology 
of the International League Against Epilepsy. Epilepsia 
1989;30(4):389-399.
33. Diagnostic Product Corporation, 1987. Albumin-Related 
Artifacts in Free Thyroid Hormone Assays. Los Angeles. 
34. Witherspoon LR, el Shami AS, Shuler SE, Neely H, Sonnemake 
R, Gilbert SS, Alyea K. Chemically blocked analog assays for free 
thyronines. I. The effect of chemical blockers on T4 analog and 
T4 binding by albumin and by thyroxin-binding globulin. Clin 
Chem 1988:34(1):9-16.
35. Babson AL, Olson DR, Palmieri T, Ross AF, Becker DM, Mulqueen 
PJ. The IMMULITE assay tube: a new approach to heterogeneous 
ligand assay. Clin Chem 1991;37(9):1521-1522.
36. Zimmermann P, Takala T, Poyhonen L, Punnonen R. 
Ultrasonography of the thyroid gland in pregnancies 
complicated by autoimmune thyroid disease. J Clin Ultrasound 
1993;21(12):109–113.
37. Hamed SA. Neuroendocrine hormonal conditions in epilepsy: 
relationship to reproductive and sexual functions. Neurologist 
2008,14(3):157-169. 
38. Villa SM, Alexander NM. Carbamazepine (Tegretol) inhibits in 
vivo iodide uptake and hormone synthesis in rat thyroid glands. 
Endocr Res 1997;13(4):385-397.
39. Surks MI, DeFesi CR. Normal serum free thyroid hormone 
concentrations in patients treated with phenytoin or 
carbamazepine. JAMA 1996;275(19):149-158.
40. Gerber H, Huber G, Peter HJ, Kämpf J, Lemarchand-Beraud 
T, Fragu P, Stocker R. Transformation of normal thyroids into 
colloid goiters in rats and mice by diphenylthiohydantoin. 
Endocrinology 1994;135(6):2688-2699.
41. Hirfanoglu T, Serdaroglu A, Camurdan O, Cansu A, Bideci A, 
Cinaz P, Gucuyener K. Thyroid function and volume in epileptic 
children using carbamazepine, oxcarbazepine and valproate. 
Pediatr Int 2007;49(6):822-826.
42. Spacilova J, Limanova Z, Aschermann M. Subclinical 
hypothyroidism with emphasis on the cardiovascular system. 
Cas Lek Cesk 2003;142(11):643-647.
43. Weissel M. Possible consequences of subclinical hypothyroidism. 
Acta Med Austriaca 2003;30(4):93-97. 
 
Where Doctors exchange clinical experiences,  
review their cases and share clinical knowledge.  
You can also access lots of medical publications for 
free. Join Now! 
http://medicalia.org/
Comment on this article:
Neurology and Neuroscience (jneuros.com) is a hybrid, peer-
reviewed journal that considers articles concerned with any 
aspect of clinical neurosciences such as neurology, psychiatry 
and neurosurgery, as well as basic research on neuroscience 
where neurologists and neuroscientists publish together.
Submit your manuscript here:
http://www.jneuros.com
Publish with iMedPub
http://www.imed.pub
